The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 19, 2022
Filed:
Feb. 24, 2017
Amgen Inc., Thousand Oaks, CA (US);
Sean P. Brown, Agoura Hills, CA (US);
David Karl Bedke, North Attleboro, MA (US);
Michael R. Degraffenreid, San Francisco, CA (US);
Jiasheng Fu, Foster City, CA (US);
Zhihong Li, Millbrae, CA (US);
Felix Gonzalez Lopez De Turiso, Cambridge, MA (US);
Ana Gonzalez Buenrostro, San Mateo, CA (US);
Michael W. Gribble, Jr., Somerville, MA (US);
Michael G. Johnson, San Francisco, CA (US);
Todd J. Kohn, Thousand Oaks, CA (US);
Kexue Li, Newbury Park, CA (US);
Yunxiao Li, Thousand Oaks, CA (US);
Mike Elias Lizarzaburu, Pacifica, CA (US);
Yosup Rew, Foster City, CA (US);
Joshua Taygerly, San Francisco, CA (US);
Yingcai Wang, Millbrae, CA (US);
Xuelei Yan, Foster City, CA (US);
Ming Yu, Foster City, CA (US);
Jiang Zhu, Palo Alto, CA (US);
Manuel Zancanella, San Mateo, CA (US);
Xian Yun Jiao, Belmont, CA (US);
Liusheng Zhu, Foster City, CA (US);
Xianghong Wang, Dublin, CA (US);
Julio C. Medina, San Carlos, CA (US);
Jason A. Duquette, Millbrae, CA (US);
Jonathan B. Houze, Cambridge, MA (US);
Marc Vimolratana, New York, NY (US);
Mario G. Cardozo, San Francisco, CA (US);
Alan C. Cheng, San Francisco, CA (US);
AMGEN INC., Thousand Oaks, CA (US);
Abstract
Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.